论文部分内容阅读
目的：观察环磷酰胺联合吡柔比星﹑5-氟尿嘧啶的新辅助化疗方案即(CTF方案)诊疗Ⅲ期乳腺癌的疗效。方法经穿刺﹑彩超﹑钼靶摄片证实为Ⅲ期乳腺癌128例﹐所有128例患者术前均用CTF方案化疗2疗程﹐疗程结束后7d手术治疗。结果所有128例患者无完全缓解患者﹐化疗后部分缓解PR30例﹐轻度缓解MR68例﹐无变化NC30例﹐总有效率76.56﹪﹐无临床进展病例﹐2疗程化疗结束后﹐28例肿瘤体积明显缩小﹔80例肿瘤轻度缩小﹐39例淋巴结明显缩小﹐15例淋巴结完全消失。结论Ⅲ期乳腺癌患者使用CTF的新辅助化疗方案后再进行手术治疗﹐可以使肿瘤缩小﹐淋巴结缩小或消失﹐降低临床分期﹐有助于手术治疗及术式选择﹐为术后辅助化疗提供指导。“,”Objective To observe the clinical efficacy of cyclophosphamide in combination with 5-Fu and pirarubicin (the CTF neoadjuvant chemotherapy regimen) in the treatment of stage Ⅲ breat cancer. Methods 128 patients with proved stage Ⅲ breat cancer were treated with CTF regimen for 2 courses, and 7 days later received operation. Results In the whole 128 cases, the total response rate was 76.56%, and the partial response (PR), minor response (MR), and no change (NC) were 30, 68, and 30 cases, respectively. There were no complete response (CR) and advanced cases After the 2 courses of chemotherapy, the gross tumor volume was obviously diminished in 28 cases and partially diminished in 80 cases. Accordingly, the notable diminution of LN was observed in 39 cases, and the effacement of LN was monitored in 15 cases. Conclusion The CTF neoadjuvant chemotherapy regimen, for patients with stageⅢbreat cancer, was effective and recommendable by down-size and down-stage, and can help the surgeons have more choices for operation.